Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of IM23 CAR-T in CD123+ AML
NCT03585517Phase 1Completed
- Sponsor
- Immunochina Pharmaceuticals
- Start
- Jul 2018
- Primary completion
- Aug 2020
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IM-23 in acute myeloid leukemia (AML), sponsored by Immunochina Pharmaceuticals. Primary endpoint: Occurrence of study related adverse events at 2 years. Started Jul 2018; status: completed.
02
Drugs
IM-23
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03585517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03585517.